{
    "clinical_study": {
        "@rank": "127701", 
        "acronym": "ELAD", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide", 
                "arm_group_type": "Experimental", 
                "description": "Daily administration of 1.8 mg liraglutide by subcutaneous injection"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Daily administration of matched placebo by subcutaneous injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study\n      in patients with mild Alzheimer's dementia (AD). The investigators aim to recruit patients\n      with mild Alzheimer's dementia as defined by the National Institute of Neurological and\n      Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorder Association\n      (NINCDS-ADRDA) Criteria for Probable Alzheimer's Dementia or meeting Dubois criteria for\n      early AD, with Mini Mental State Evaluation score of at least 22 out of a maximum of 30 and\n      a CDR Global score of 0.5 or 1.\n\n      Patients will be randomised on a 1:1 ratio to receive liraglutide or identical matching\n      placebo."
        }, 
        "brief_title": "Evaluating Liraglutide in Alzheimer's Disease", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Capable of giving and capacity to give informed consent. (Advanced directive will be\n             taken from all patients regarding whether they would like to continue in the study in\n             case they lose their capacity during the study. Carers will be actively involved in\n             the consent process at the beginning of the study)\n\n          2. A carer who can act as a reliable study partner\n\n          3. Diagnosis of Probable Alzheimer's disease according to Dubois criteria (Dubois,\n             Feldman et al. 2007) or National Institute of Neurological and Communicative\n             Disorders and Stroke-Alzheimer's Disease and Related Disorders Association\n             (NINCDS-ADRDA) criteria\n\n          4. Age from 50 to 85 years, inclusive\n\n          5. Mini-Mental State Examination (MMSE) score of \u226522\n\n          6. Rosen Modified Hachinski Ischemic score \u22644\n\n          7. On stable medication for 3 months; on or off cholinesterase inhibitors\n\n          8. Fluency in English and evidence of adequate premorbid intellectual functioning\n\n          9. Likely to be able to participate in all scheduled evaluations and complete all\n             required tests\n\n        Exclusion Criteria:\n\n          1. Diabetes\n\n          2. Any contraindications to the use of liraglutide as per the Summary of Product\n             Characteristics. (hepatic impairment, renal impairment with CKD stage 3 and above,\n             inflammatory bowel disease)\n\n          3. Significant neurological disease other than AD that may affect cognition\n\n          4. MRI/CT showing unambiguous aetiological evidence of cerebrovascular disease with\n             regard to their dementia\n\n          5. Currently taking or having taken memantine on the 30 days prior to screening\n\n          6. Current presence of a clinically significant major psychiatric disorder (e.g., Major\n             Depressive Disorder) according to the criteria of the Diagnostic and Statistical\n             Manual of Mental Disorders, Fourth Edition (DSM-IV)\n\n          7. Current clinically significant systemic illness that is likely to result in\n             deterioration of the patient's condition or affect the patient's safety during the\n             study\n\n          8. History of seizures, excluding febrile seizures in childhood\n\n          9. Treatment with immunosuppressive medications (e.g. systemic corticosteroids) within\n             the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for\n             asthma are permitted) or chemotherapeutic agents for malignancy within the last 3\n             years\n\n         10. Myocardial infarction within the last 1 year\n\n         11. History of cancer within the last 5 years\n\n         12. Other clinically significant abnormality on physical, neurological or laboratory\n             examination that could compromise the study or be detrimental to the patient\n\n         13. History of alcohol or drug dependence or abuse within the last 2 years\n\n         14. Current use of anticonvulsant, anti-Parkinson's, anticoagulant (excluding the use of\n             aspirin 325 mg/day or less) or narcotic medications\n\n         15. Use of experimental medications for AD or any other investigational medication or\n             device within 60 days. Patients who have been involved in a monoclonal antibody study\n             are excluded unless it is known that they were receiving placebo in that trial\n\n         16. Women of childbearing potential. Women who could become pregnant will be required to\n             use adequate contraception throughout the trial\n\n         17. Patients with a personal or family history of medullary thyroid carcinoma (MTC) and\n             patients with multiple endocrine neoplasia type 2 (MEN2)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "206", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843075", 
            "org_study_id": "U1111-1131-9252"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liraglutide", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug", 
                "other_name": "Victoza"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glucagon-Like Peptide 1"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "v.tsipouri@imperial.ac.uk", 
                "last_name": "Vicky Tsipouri, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "W12 0NN"
                }, 
                "name": "Imperial College, Hammersmith Hospital"
            }, 
            "investigator": {
                "last_name": "Paul Edison, PhD FRCP(I)", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)", 
        "overall_contact": {
            "email": "paul.edison@imperial.ac.uk", 
            "last_name": "Paul Edison, MBBS PhD FRCPI", 
            "phone": "+44 (0) 2033133275"
        }, 
        "overall_contact_backup": {
            "email": "v.tsipouri@imperial.ac.uk", 
            "last_name": "Vicky Tsipouri, PhD"
        }, 
        "overall_official": {
            "affiliation": "Imperial College London", 
            "last_name": "Paul Edison, MBBS, PhD, FRCPI", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change in cerebral glucose metabolic rate from baseline to follow up (12 months) in the treatment group compared with the placebo group.", 
            "measure": "The change in cerebral glucose metabolic rate", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843075"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The change in z-scores for the ADAS Exec, MRI changes, microglial activation, and CSF markers", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The incidence and severity of treatment emergent adverse events or clinically important changes in safety assessments over 12 months.", 
                "measure": "The incidence and severity of treatment emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Imperial College London", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "King's College Hospital NHS Trust", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Oxford", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Southampton", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Avon and Wiltshire Mental Health Partnership NHS Trust", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Imperial College London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}